- Home
- ADT vs LEGN Comparison
ADT vs LEGN Comparison
Compare ADT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADT | LEGN |
|---|---|---|
| Founded | 1874 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.9B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ADT | LEGN |
|---|---|---|
| Price | $7.30 | $24.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $8.17 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 8.0M | 1.6M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | ★ 29.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,128,607,000.00 | N/A |
| Revenue This Year | $1.90 | $42.68 |
| Revenue Next Year | $2.91 | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.70 | N/A |
| 52 Week Low | $6.27 | $16.24 |
| 52 Week High | $8.94 | $45.30 |
Technical Indicators
Market Signals| Indicator | ADT | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.73 | 78.54 |
| Support Level | $6.27 | $17.01 |
| Resistance Level | $8.27 | $28.97 |
| Average True Range (ATR) | 0.16 | 1.21 |
| MACD | 0.10 | 0.63 |
| Stochastic Oscillator | 90.86 | 79.40 |
Price Performance
Historical ComparisonAbout ADT ADT Inc.
ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.